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Economic evaluation in health (also known as pharmacoeconomic in case of medicines) 
identifies, measures, and values costs and outcomes of alternative healthcare technologies, and 
can be performed alongside controlled clinical trials, but analytical modelling is usually used. 
Decision trees and Markov models are the two most common approaches used in economic 
evaluation. The biggest advantages of a decision tree are clarity, simplicity, and 
straightforwardness. On the other hand, the main advantage of the Markov model is its ability to 
incorporate complex events into the simulation, which is practically impossible to do with a 
decision tree. Reimbursement policy in Serbia mandatorily incorporates economic evaluations to 
promote availability and accessibility of the prescription medicines. To show current 
pharmacoeconomic value of a medicine, budget impact analysis and the cost-effectiveness 
analysis should be included. The latter should be conducted using appropriate modelling 
techniques. However, since no official methodological guidelines about the modelling and 
economic analysis exist, the submissions by marketing authorization holders vary greatly. The 
future of pharmacoeconomic modelling depends on the research area of interest, with new 
frameworks and approaches being developed. 
 









Modern health systems are under enormous financial pressure. In this context, it is 
increasingly important to demonstrate that new healthcare technologies provide 
consistent health gains at reasonable costs compared to alternative use of resources. 
The methodology commonly used to analyse this issue is called economic 
evaluation. Economic evaluation can be defined as a set of research methods that 
identifies, measures, and values costs and outcomes of alternative healthcare technologies 
(1). When economic evaluation is applied specifically to pharmaceutical products, it is 
known as pharmacoeconomics. Economic evaluation in healthcare has its foundation in 
economic science, especially welfare economy, but also applies a wide range of scientific 
disciplines such as epidemiology, psychology, or decision analysis (2, 3).  
Economic evaluations are currently used in two main contexts: (I) in decision 
making to optimise medicine prescribing by health care professionals, and (II) in decision 
making by regulatory authorities and policy makers in respect to reimbursement of 
medicines. 
Economic evaluations can be performed alongside controlled clinical trials (4), but 
usually, analytical modelling as an alternative option is used. Modelling in economic 
evaluation implies the use of mathematical techniques and computer software to 
incorporate information from multiple different sources to evaluate costs and outcomes 
of alternative healthcare technologies. Various models can be used in the economic 
evaluation of healthcare (5, 6), but decision trees and Markov models remain the two 
most common approaches (7, 8). 
Decision trees 
A decision tree is the simplest analytical model used in economic evaluation. Figure 
1 shows a hypothetical example of a decision about the treatment of a disease X. There 
are two possible alternatives, represented as branches: no therapy or start therapy with 
medicine A. The choice between these two alternatives is represented graphically as a 
square or decision node. Independently of the chosen alternative, the clinical pathway 
allows the patient’s recovery or its alternative without recovery, which is characterised 
by chance node (circle). All events in the clinical pathway that follow each option are 
linked with probabilities and must be mutually exclusive. The sum of probabilities for 
each alternative must be the value of one. At the end of each branch is a terminal node, 
represented by a triangle, to which consequences of health technology, called payoffs, are 
assigned. The payoffs can be any type of outcomes: clinical (e.g. life years), economic 
(costs), or humanistic (e.g. quality-adjusted life years, QALYs). QALY, as a single 
measure, combines the patient’s quantity (life expectancy) and quality of life, thereby 
providing a common index that facilitates comparisons of therapy outcomes across 
different diseases. QALY is calculated by multiplying the time spent in a certain health 
state by the utility or preference weight linked with that state. The utility weights can be 





Figure 1.  Hypothetical example of a decision tree 
Slika 1.  Hipotetički izgled modela drvo odlučivanja 
 
The probabilities (expressed in form of rates, counts, relative risks or odds ratios) 
and payoff values can usually be found in published literature, but in the absence of 
publicly available data, expert opinions can be used. The costs can be calculated using 
official price lists for medicines or health services.  
Once the decision tree has been properly designed and all probabilities and payoffs 
added, the evaluation of the model can be performed. This process is also known as “roll-
back” since the calculation is done by multiplying the values of payoff (right side of the 
tree) with the respective values of probability (left side of the tree) and summing up all 
these values (10, 11). 
 The greatest advantages of a decision tree are clarity, simplicity, and 
straightforwardness. The main disadvantage of a decision tree is the omission of its use 
in time-dependent models, such as in chronical diseases where the events are recurring 
and where transition of health events occurs. 
The application of decision trees in clinical practice in Serbia has been recognized 
in different areas, including screening procedures (12), pharmacotherapy of infectious 
diseases (13, 14), labour for singleton pregnancy (15) and pharmacist service (16). 
Markov models 
Markov models (named after the Russian mathematician Andrey Andreyevich 




such, they are applied in economic evaluations of medications used in different chronic 
diseases or conditions. 
Any Markov model consists of a finite number of mutually exclusive health states. 
At any point in time, the patient can reside in only one of those health states. The 
movement of the patient between health states is defined by transition probabilities. In 
the Markov model, time is presented in discrete intervals called cycles, at which the 
patient can move between health states or remain in the current one (1, 11). 
Figure 2 illustrates the simplest Markov model consisting of three health states: 
healthy, sick, and dead. The arrows represent the possible transitions between the health 
states while loops indicate the possibility of remaining in a current health state. 
 
Figure 2.  Hypothetical example of a Markov model  
Slika 2.  Hipotetički izgled Markovljevog modela 
 
 In the Markov model, the sum of transition probabilities out of health states must 
be one. Let’s say that the probability of moving from “well” to “sick” health state is 0.2 
at the end of each cycle. At the same time, probability of moving from “well” to “dead” 
health state is 0.1. This means that the probability of remaining in health state “well” must 
be 0.7 (calculation: 1-0.2-0.1=0.7). The process of transition is repeated after each cycle 
until a termination rule is reached. Usually, the termination rule is defined by the specific 
number of cycles, or until the entire cohort (population) reaches the so-called absorbing 
state, meaning the state that can’t be left. In Figure 2, this state is “dead”.  
 As previously stated, values for probabilities and payoffs can be found in and 
taken over from published literature or be defined by medical experts. The evaluation of 




Payoffs can be expressed as costs, life years, utilities, etc. The expected values are 
calculated in a similar manner, by multiplying the percent of the cohort in each state with 
the costs or outcomes assigned to that state. Finally, the expected costs and outcomes are 
totalled across the cycles.   
The main advantage of the Markov model is its ability to incorporate complex 
events into the simulation. This is practically impossible to do with a decision tree. 
Moreover, one of its key strengths is the ability to translate data from the individual level 
to the level of population. On the other hand, this advantage may potentially lead to one 
of the model's limitations, such as disregard of heterogeneity (17). Microsimulation 
models and their extension, agent-based modelling, are proposed to overcome the 
limitation on heterogeneity when modelling the distribution of individual lifespans is 
needed (knowing the individual progress over time) (17, 18). 
However, the main limitation of the Markov model is memorylessness or Markov 
assumption, which means that the probability of a given transition in the model is 
independent of the nature or timing of earlier transitions. In the given example, this 
corresponds to the probability of dying being independent of the time the individual spent 
in the “well” health state before moving to the “sick” health state.  
 The practical application of the Markov model in Serbia has been recognized in 
different diseases (19-22), and within biochemical markers (23,24). 
 Economic evaluations and modelling in Serbia 
In an attempt to control expenses and evaluate the value of new medicines, 
economic evaluations are increasingly used by decision makers, regulatory bodies, and 
health insurance funds all around the world.  
Besides the procedure for obtaining marketing authorization for a medicine at the 
Medicines and Medical Devices Agency of Serbia, the marketing authorization holder 
needs to fulfil additional steps to ensure the availability of the medicines in the market. 
The first is to determine the maximum wholesale price for the medicine. The institutions 
responsible for this step are the Ministry of Health and Ministry of Trade, Tourism and 
Telecommunications. According to the regulation, one of the mandatory criteria in 
determining the maximum medicine price is pharmacoeconomic evaluation (25). The 
term “pharmacoeconomic evaluation” is used only to mark selected indicators, such as 
cost per daily defined dose, monthly or annual costs of therapy, and comparative analysis 
of costs and outcomes of medicine use (25). Although the last indicator corresponds to 
the definition of economic evaluation (1), current practices show that different types of 
submitted materials are accepted. At this point, marketing authorization holders may 
prepare and submit one of the models that describe and evaluate costs and outcomes of 
the medicine. However, this is usually not done.  
After obtaining the maximum price of medicines, the marketing authorization 
holders may distribute medicines through pharmacies. However, for a significant majority 




reimbursement of medicines by the Republic Fund of Health Insurance. In this way, the 
marketing authorization holder assures better availability of the medicines, which is 
especially important in the case of new, innovative medicines. 
The Republic Health Insurance Fund is the authority responsible for making the 
decision on the reimbursement policy of the medicine. According to the bylaw that 
regulates conditions, criteria, way, and procedure for reimbursement of medicines, the 
request for medicines to be included in the Positive list should comprise, among other 
documents, the results of the pharmacoeconomic evaluation of medicine (26). Among the 
pharmacoeconomic evaluations, analyses that are required are: budget impact analysis 
and cost-effectiveness analysis (for: innovative medicines, new original medicines and 
where a comparative medicine exists and is already included within the Positive list), that 
“should be conducted using appropriate modelling techniques (decision tree, Markov 
model, Monte Carlo simulation – multiple simulations of a model often used in 
uncertainty analysis, or other similar models), customized according to the current 
situation in the Republic of Serbia” (26). At this point, the marketing authorization holder 
is obliged to prepare and submit one of the models that describe and evaluate costs and 
outcomes of alternative medicines. However, since no official methodological guidelines 
about the modelling and the economic analysis in general exist, the submissions vary 
greatly. The existence of guidelines would increase consistency, quality, and uniformity 
of the submitted files, but also the transparency of the whole process. The development 
of the guidelines is usually done in two stages, in which experts from academia play an 
important role (27, 28).  
Modelling in public health interventions 
Development and promotion of different programs for raising awareness about the 
importance and significance of health promotion, prevention of different diseases and 
their complications have been rapidly increasing in the past years (29). 
Along with the two main contexts of economic evaluation (optimising medicine 
prescribing by health care professionals, and support in decision making by regulatory 
authorities and policy makers in respect to the reimbursement of medicines.), its 
application can be also widened with the inclusion of public health interventions (PHIs) 
by health care professionals. Two important questions need to be answered before 
implementing the new PHI: “Is the new PHI worthwhile?’, and “Could the money for the 
new PHI be better spent on alternative programme(s)?”. Economic evaluation and 
modelling can help with both questions (29). 
It is considered that traditional economic evaluation methods are well established, 
but insufficient for the assessment of PHI. With respect to that, economic modelling can 
be an ideal tool for PHI assessment, even though some challenges exist. It has been 
proposed that the decision analytic model (DAM) can be used for this purpose (29). This 
is a mathematical decision-making tool used to integrate evidence on costs and outcomes 
from different sources in order to notify decision makers about the resource allocation in 




Briggs and colleagues (11) suggested and adopted decision analysis as a robust 
framework when conducting economic evaluations of health technologies and PHIs, and 
they propose basic steps for DAM provided (Figure 3). 
 
 
Figure 3.  Framework for conducting the decision analytic model 
Slika 3. Okvir u sprovođenju analitičkog modela odluke 
 
The third step of the DAM requires the application of pharmacoeconomic analyses. 
The most commonly used analyses are decision tree, Markov model, discrete event 
simulation, agent-based modelling, and system dynamics. Dynamic models are 
considered to be the proper model for modelling infectious diseases, and it is supposed 
that they also can be used for modelling in PHIs. In those cases, the DAM model should 
be determined by exploring different factors such as decision-makers' requirements, the 
complexity of the disease or health care area, modellers’ expertise, or preference (29, 30). 
There are many challenges for modelling in PHIs. Squires and Boyd summarized 
the features of public health systems along with modelling challenges, current practices, 
and latest methodological research that could provide potential solutions for challenges 
in practice (29). Approaches suggested to try and overcome challenges are early-stage 
decision modelling with an iterative approach to economic evaluation of PHIs. The stages 








Figure 4.  Steps in iterative approach in economic evaluation 
Slika 4.  Koraci u iterativnom pristupu u ekonomskim evaluacijama 
 
According to Squires and Boyd, the key principles of good practice for developing 
the structure of public health economic models are: (I) system approaches to public health 
modelling should be taken into account; (II) understanding of the public health problem 
is an imperative prior to and alongside developing and justifying the model structure; (III) 
strong communication with stakeholders and members included in the model 
development is essential; (IV) a systematic consideration of the determinants of health is 
central to identifying all key impacts of the interventions within public health economic 
modelling (29). 
 Future of modelling 
The decision tree and Markov model are still the most widely used analytical 
modelling techniques in health evaluations. However, the future of pharmacoeconomic 
modelling depends on the area of research interest and demand for modelling. New 
frameworks and approaches, as well as new modelling techniques are being developed 
and future research should pay more attention to widening and promoting their usage 
(e.g., conceptual modelling framework, early-stage decision modelling, iterative 
framework). These new approaches could overcome challenges that are present in current 
practice and usually used models. Since the interest in public health has rapidly increased 
in the last decade, this area could benefit the most from modelling in economic 
evaluations, and consequently also society, healthcare systems, decision makers and any 
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Kratak sadržaj  
Ekonomske evaluacije u zdravstvu (ili farmakoekonomija u slučaju lekova) identifikuju, 
vrednuju i mere troškove i ishode alternativnih zdravstvenih tehnologija, i mogu se sprovoditi 
paralelno sa kliničkim studijama, ali se češće primenjuje modelovanje. Drvo odlučivanja i 
Markovljev model su dva najčešće korišćena modela u ekonomskim evaluacijama. Najveća 
prednost primene drveta odlučivanja je njegova jednostavnost, jasnoća i direktnost. Sa druge 
strane, najveća prednost Markovljevog modela je sposobnost da uključi kompleksne događaje u 
simulaciju, što je praktično nemoguće sa drvetom odlučivanja. Ekonomske evaluacije su 
obavezan zahtev u nekoliko procesa u cilju povećanja dostupnosti lekova u Srbiji. Kako bi se 
pokazala sadašnja farmakoekonomska prednost leka neophodno je sprovesti analizu uticaja na 
budžet i analizu troškovne isplativosti. Drugu analizu je neophodno sprovesti primenom 
odgovarajuće tehnike modelovanja. Međutim, kako ne postoje zvanične smernice o modelovanju 
i ekonomskim evaluacija, dokumentacija podneta od strane nosioca dozvole pokazuje značajno 
variranje. Budućnost modelovanja u farmakoekonomiji zavisi od istraživačkog interesa, pri čemu 
se razvijaju novi okviri i pristupi.  
 
Ključne reči: farmakoekonomske evaluacije, modelovanje, drvo odlučivanja,  
   Markovljev model 
 
 
 
 
 
